Skip to main content


Fig. 2 | Clinical Epigenetics

Fig. 2

From: Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

Fig. 2

Chemosensitizing effect of the combination vorinostat with decitabine. a Treatment schedule performed in OCI-Ly1 cells receiving vorinostat (VST) and decitabine (DAC) followed by doxorubicin (Doxo) or mechlorethamine (Mechlo) (upper part), and mRNA and protein levels of p21 after 5 days of treatment (lower part). b Reduction in the growth inhibition 50 (GI50) values for mechlorethamine and doxorubicin after treatment with the VST and DAC combination. c Treatment schedule for mice receiving vehicle, VST, DAC, or VST + DAC, followed by doxorubicin (left part). On the right part, area under the curve (AUC) of tumor growth curves in OCI-Ly7-treated xenografts. d Representative images from OCI-Ly7 mice tumors after being treated, assayed for apoptosis by TUNEL. The percentages of stained area (mean ± the standard error) are shown at the bottom. The bar represents 100 μm

Back to article page